These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37399857)

  • 41. New Potential Treatments for Resistant Hypertension.
    Janakiraman A; Cohen DL
    Curr Cardiol Rep; 2023 Nov; 25(11):1443-1449. PubMed ID: 37755638
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Future pharmacological therapy in hypertension.
    Stewart MH; Lavie CJ; Ventura HO
    Curr Opin Cardiol; 2018 Jul; 33(4):408-415. PubMed ID: 29702500
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study.
    Jaffe G; Gray Z; Krishnan G; Stedman M; Zheng Y; Han J; Chertow GM; Leppert JT; Bhalla V
    Hypertension; 2020 Mar; 75(3):650-659. PubMed ID: 32008436
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue?
    Manolis AA; Manolis TA; Melita H; Manolis AS
    Curr Hypertens Rep; 2019 Mar; 21(3):22. PubMed ID: 30826898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
    Funder JW
    Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.
    Lim PO; Jung RT; MacDonald TM
    Br J Clin Pharmacol; 1999 Nov; 48(5):756-60. PubMed ID: 10594479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recent progress in the diagnosis and treatment of primary aldosteronism.
    Yoshida Y; Shibata H
    Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
    Gross E; Rothstein M; Dombek S; Juknis HI
    Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Update in primary aldosteronism.
    Stowasser M
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3623-30. PubMed ID: 19737921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New drugs, procedures, and devices for hypertension.
    Laurent S; Schlaich M; Esler M
    Lancet; 2012 Aug; 380(9841):591-600. PubMed ID: 22883508
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension.
    Dey S; Frishman WH; Aronow WS
    Cardiol Rev; 2023 Aug; ():. PubMed ID: 37548462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antihypertensive therapy: role of aldosterone antagonists.
    Grandi AM
    Curr Pharm Des; 2005; 11(17):2235-42. PubMed ID: 16026292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension.
    Dudenbostel T; Calhoun DA
    Am J Hypertens; 2017 Feb; 30(2):103-109. PubMed ID: 27609503
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reviving the use of aldosterone inhibitors in treating hypertension in obesity.
    Huby AC; Belin De Chantemèle EJ
    Am J Physiol Regul Integr Comp Physiol; 2015 Nov; 309(9):R1065-7. PubMed ID: 26157057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system.
    Nishiyama A; Hasegawa K; Diah S; Hitomi H
    J Pharmacol Sci; 2010; 113(4):310-4. PubMed ID: 20675957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [What are the pharmacological options for treating resistant hypertension?].
    Martell-Claros N; Abad-Cardiel M
    Hipertens Riesgo Vasc; 2017 Jan; 34 Suppl 1():25-28. PubMed ID: 29703399
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension.
    Hoyt SB; Taylor J; London C; Ali A; Ujjainwalla F; Tata J; Struthers M; Cully D; Wisniewski T; Ren N; Bopp C; Sok A; Verras A; McMasters D; Chen Q; Tung E; Tang W; Salituro G; Clemas J; Zhou G; MacNeil D; Duffy R; Xiong Y
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2384-2388. PubMed ID: 28416132
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aldosterone Synthase in Peripheral Sensory Neurons Contributes to Mechanical Hypersensitivity during Local Inflammation in Rats.
    Mohamed DM; Shaqura M; Li X; Shakibaei M; Beyer A; Treskatsch S; Schäfer M; Mousa SA
    Anesthesiology; 2020 Apr; 132(4):867-880. PubMed ID: 32011337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.